The potential for skin rash to be used as a predictor of therapeutic response to TKIs6, 12, 13 lies in the fact that skin injuries are “on-target” effects caused by the down-stream inhibition of EGFR signaling that interferes the proper function of epidermal cells14, 15, 16. This evidence concerns the gene EGFR and Skin rash.